Obesity Science & Innovation Sep 24, 2026 TO Sep 25, 2025 | Boston, MA The Obesity Science & Innovation event drives the future of obesity therapeutics by bringing together the most innovative companies with the right partners
116 However, clinical studies using GSH as a therapeutic agent have shown mixed results
However, some people may experience more severe side effects, such as pancreatitis (inflammation of the pancreas), gallbladder problems, or allergic reactions
Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial
Core nutritional information forms the foundation of useful meal logs: Timing of meals and snacks GLP-1 medications significantly affect gastric emptying, making meal timing relevant to symptom management Portion sizes Even approximate estimates help identify whether reduced appetite is leading to inadequate intake Protein content Including a source of protein at each meal is important
Reduce dose by 50% for 35 days, then re-escalate slowly